Pasithea Therapeutics Corp. (NASDAQ:KTTA) Sees Significant Increase in Short Interest

Pasithea Therapeutics Corp. (NASDAQ:KTTA) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 25,800 shares, a growth of 37.2% from the December 15th total of 18,800 shares. Based on an average daily volume of 40,700 shares, the short-interest ratio is currently 0.6 days. Currently, 2.5% of the shares of the company are sold short.

Pasithea Therapeutics Stock Performance

NASDAQ KTTA opened at $2.46 on Thursday. The company has a 50-day moving average price of $2.93 and a two-hundred day moving average price of $4.11. Pasithea Therapeutics has a 52 week low of $2.20 and a 52 week high of $9.25.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.